While some researchers still claim that embryonic stem cells (ESCs) offer the best hope for treating many debilitating diseases, there is now a great deal of evidence contrary to that theory. Use of stem cells obtained by destroying human embryos is not only unethical but presents many practical obstacles as well.
"Major roadblocks remain before human embryonic stem cells could be transplanted into humans to cure diseases or replace injured body parts, a research pioneer said Thursday night. University of Wisconsin scientist James Thomson said obstacles include learning how to grow the cells into all types of organs and tissue and then making sure cancer and other defects are not introduced during the transplantation. 'I don't want to sound too pessimistic because this is all doable, but it's going to be very hard,' Thomson told the Wisconsin Newspaper Association's annual convention at the Kalahari Resort in this Wisconsin Dells town. 'Ultimately, those transplation therapies should work but it's likely to take a long time.'....Thomson cautioned such breakthroughs are likely decades away."
-Associated Press reporter Ryan J. Foley "Stem cell pioneer warns of roadblocks before cures," San Jose Mercury News Online, posted on Feb. 8, 2007, http://www.mercurynews.com/mld/mercurynews/16656570.htm
"Although embryonic stem cells have the broadest differentiation potential, their use for cellular therapeutics is excluded for several reasons: the uncontrollable development of teratomas in a syngeneic transplantation model, imprinting-related developmental abnormalities, and ethical issues."
-Gesine Kgler et al., "A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation Potential," Journal of Experimental Medicine, Vol. 200, No. 2 (July 19, 2004), p. 123.
From a major foundation promoting research in pancreatic islet cells and other avenues for curing juvenile diabetes:
"Is the use of embryonic stem cells close to being used to provide a supply of islet cells for transplantation into humans?
"No. The field of embryonic stem cells faces enormous hurtles to overcome before these cells can be used in humans. The two key challenges to overcome are making the stem cells differentiate into specific viable cells consistently, and controlling against unchecked cell division once transplanted. Solid data of stable, functioning islet cells from embryonic stems cells in animals has not been seen."
-"Q & A," Autoimmune Disease Research Foundation, http://www.cureautoimmunity.org/Q%20&%20A.htm, accessed July 2004.
"'I think the chance of doing repairs to Alzheimer's brains by putting in stem cells is small,' said stem cell researcher Michael Shelanski, co-director of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain at the Columbia University Medical Center in New York, echoing many other experts. 'I personally think we're going to get other therapies for Alzheimer's a lot sooner.'...
"[G]iven the lack of any serious suggestion that stem cells themselves have practical potential to treat Alzheimer's, the Reagan-inspired tidal wave of enthusiasm stands as an example of how easily a modest line of scientific inquiry can grow in the public mind to mythological proportions.
"It is a distortion that some admit is not being aggressively corrected by scientists.
"'To start with, people need a fairy tale,' said Ronald D.G. McKay, a stem cell researcher at the National Institute of Neurological Disorders and Stroke. 'Maybe that's unfair, but they need a story line that's relatively simple to understand.'"
-Rick Weiss, "Stem Cells an Unlikely Therapy for Alzheimer's," Washington Post, June 10, 2004, p. A3.
"ES [embryonic stem] cells and their derivatives carry the same likelihood of immune rejection as a transplanted organ because, like all cells, they carry the surface proteins, or antigens, by which the immune system recognizes invaders. Hundreds of combinations of different types of antigens are possible, meaning that hundreds of thousands of ES cell lines might be needed to establish a bank of cells with immune matches for most potential patients. Creating that many lines could require millions of discarded embryos from IVF clinics."
-R. Lanza and N. Rosenthal, "The Stem Cell Challenge," Scientific American, June 2004, pp. 92-99 at p. 94. [Editor's note: A recent study found that only 11,000 frozen embryos are available for research use from all the fertility clinics in the U.S., and that destroying all these embryos for their stem cells might produce a total of 275 cell lines. See Fertility and Sterility, May 2003, pp. 1063-9 at p. 1068.]
"Embryonic stem cells have too many limitations, including immune rejection and the potential to form tumors, to ever achieve acceptance in our lifetime. By that time, umbilical cord blood stem cells will have been shown to be a true 'gift from the gods.'"
-Dr. Roger Markwald, Professor and Chair of Cell Biology and Anatomy at the Medical University of South Carolina, quoted in "CureSource Issues Statement on Umbilical Cord Blood Stem Cells vs. Embryonic Stem Cells," BusinessWire, May 12, 2004, also at http://curesource.net/why.html.
"'We're not against stem-cell research of any kind,' said [Tulane University research professor Brian] Butcher. 'But we think there are advantages to using adult stem cells. For example, with embryonic stem cells, a significant number become cancer cells, so the cure could be worse than the disease. And they can be very difficult to grow, while adult stem cells are easy to grow.'"
-Heather Heilman, "Great Transformations," The Tulanian (Spring 2004 issue), at http://www2.tulane.edu/article_news_details.cfm?ArticleID=5155.
"There are still many hurdles to clear before embryonic stem cells can be used therapeutically. For example, because undifferentiated embryonic stem cells can form tumors after transplantation in histocompatible animals, it is important to determine an appropriate state of differentiation before transplantation. Differentiation protocols for many cell types have yet to be established. Targeting the differentiated cells to the appropriate organ and the appropriate part of the organ is also a challenge."
-E. Phimister and J. Drazen, "Two Fillips for Human Embryonic Stem Cells," New England Journal of Medicine, Vol. 350 (March 25, 2004), pp. 1351-2 at 1351.
Harvard researchers, trying to create human embryonic stem cell lines that are more clinically useful than those now available, find that their new cell lines are already genetically abnormal:
"After prolonged culture, we observed karyotypic changes involving trisomy of chromosome 12..., as well as other changes... These karyotypic abnormalities are accompanied by a proliferative advantage and a noticeable shortening in the population doubling time. Chromosomal abnormalities are commonplace in human embryonal carcinoma cell lines and in mouse embryonic stem-cell lines and have recently been reported in human embryonic stem-cell lines."
-C. Cowan et al., "Derivation of Embryonic Stem-Cell Lines from Human Blastocysts," New England Journal of Medicine, Vol. 350 (March 25, 2004), pp. 1353-6 at 1355.
"[Johns Hopkins University] biologist Michael Shamblott said...major scientific hurdles await anybody wishing to offer a treatment, let alone a cure, based on cells culled from embryos.
"Among the major obstacles is the difficulty of getting embryonic stem cells master cells that generate every tissue in the human body to become exactly the type of cell one wants... Scientists...haven't been able to guarantee purity cells, for instance, that are destined to become muscle cells and nothing else...
"Transplanting a mixed population of cells could cause the growth of unwanted tissues. The worst case could see stem cells morphing into teratomas, particularly gruesome tumors that can contain hair, teeth and other body parts.
"Another issue is timing... Stem cells pass through many intermediate stages before they become intermediate cells such as motor neurons or pancreatic or heart cells. Deciding when to transplant remains an open question, and the answer might differ from disease to disease.
"...In tackling Lou Gehrig's disease, [Johns Hopkins neurologist Dr. Jeffrey] Rothstein figured that cells that haven't committed themselves to becoming motor neurons would stand the best chance, once implanted, of reaching out and connecting with the cells that surround them. What he found, however, is that these immature cells didn't develop much once transplanted into lab animals."
-Jonathan Bor, "Stem Cells: A long road ahead," Baltimore Sun, March 8, 2004, p. 12A.
"Tony Blau, a stem-cell researcher at the University of Washington, said it is 'extremely laborious' to keep embryonic cells growing, well-nourished and stable in the lab so they don't die or turn into a cell type with less potential. Researchers need to know how to channel the stem cells to create a specific kind of cell, how to test whether they're pure, and how to develop drugs that could serve as a sort of antidote in case infused stem cells started creating something dangerous, such as cancer.
"Big companies, Blau said, want to know that their drugs will be almost completely stable, standard, pure and consistent, because they can behave differently if they aren't. Stem cells never will achieve that kind of standardization, Blau said, because living cells are more complex than chemically synthesized drugs."
-Luke Timmerman, "Stem-cell research still an embryonic business," Seattle Times, Business & Technology section, February 22, 2004, at http://seattletimes.nwsource.com/html/businesstechnology/2001862747_stemcells22.html.
"[W]ithin the ESC research community, realism has overtaken early euphoria as scientists realize the difficulty of harnessing ESCs safely and effectively for clinical applications. After earlier papers in 2000 and 2001 identified some possibilities, research continued to highlight the tasks that lie ahead in steering cell differentiation and avoiding side effects, such as immune rejection and tumorigenesis."
-Philip Hunter, "Differentiating Hope from Embryonic Stem Cells," The Scientist, Vol. 17, Issue 34 (December 15, 2003), at http://www.the-scientist.com/yr2003/dec/hot_031215.html.
"Long-term culture of mouse ES [embryonic stem] cells can lead to a decrease in pluripotency and the gain of distinct chromosomal abnormalities. Here we show that similar chromosomal changes, which resemble those observed in hEC [human embryonal carcinoma] cells from testicular cancer, can occur in hES [human embryonic stem] cells.... The occurrence and potential detrimental effects of such karyotopic changes will need to be considered in the development of hES cell-based transplantation therapies."
-J. Draper et al., "Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells," Nature Biotechnology, Vol. 22 (2003), pp. 53-4.
"James A. Thompson of the University of Wisconsin, Madison, and his colleagues managed to isolate and culture the first human embryonic stem cells in 1997. Five years later, big scientific questions remain. [Harvard embryonic stem cell researcher Doug] Melton and his colleagues, for instance, don't yet know how to instruct the totipotent stem cells to become the specific cells missing in a diabetic person, the pancreatic beta cell.
"'Normally, if you take an embryonic stem cell, it will make all kinds of things, sort of willy-nilly,' says Melton."
-J. Mitchell, "Stem Cells 101," PBS Scientific American Frontiers, May 28, 2002, http://www.pbs.org/saf/1209/features/stemcell.htm.
"Unlike stem cells isolated from the embryo, [adult stem cells] do not carry the same risks of cancer or uncontrollable growth after transplant, and they can be isolated from patients requiring treatment, thus avoiding all problems of immune rejection and the need for immune suppressive drugs that carry their own risks.
"...Embryonic stem cells are promoted on grounds that they are developmentally more flexible than adult stem cells. But too much flexibility may not be desirable. Transplant of embryonic cells into the brains of Parkinson's patients turned into an irredeemable nightmare because the cells grew uncontrollably. Embryonic stem cells also show genetic instability and carry considerable risks of cancer... When injected under the skin of certain mice, they grow into teratomas, tumors consisting of a jumble of tissue types, from gut to skin to teeth, and the same happens when injected into the brain."
-Dr. Mae-Wan Ho and Prof. Joe Cummins on behalf of the Institute of Science in Society (ISIS), "Hushing Up Adult Stem Cells," ISIS report, February 11, 2002, at http://www.i-sis.org.uk/HUASC.php.
"'I even hear from patients whose fathers have lung cancer,' said Dr. Hogan, a professor at Vanderbilt School of Medicine. 'They have a whole slew of problems they think can be treated. They think stem cells are going to cure their loved ones of everything.'
"If it ever happens, it will not happen soon, scientists say. In fact, although they worked with mouse embryonic stem cells for 20 years and made some progress, researchers have not used these cells to cure a single mouse of a disease...
"Scientists say the theory behind stem cells is correct: the cells, in principle, can become any specialized cell of the body. But between theory and therapy lie a host of research obstacles...the obstacles are so serious that scientists say they foresee years, if not decades, of concerted work on basic science before they can even think of trying to treat a patient."
-Gina Kolata, "A Thick Line Between Theory and Therapy, as Shown with Mice," New York Times, December 18, 2001, p. F3.
"Mice cloned from embryonic stem cells may look identical, but many of them actually differ from one another by harboring unique genetic abnormalities, scientists have learned...
"The work also shows for the first time that embryonic stem cells...are surprisingly genetically unstable, at least in mice. If the same is true for human embryonic stem cells, researchers said, then scientists may face unexpected challenges as they try to turn the controversial cells into treatments for various degenerative conditions."
-Rick Weiss, "Clone Study Casts Doubt on Stem Cells," Washington Post, July 6, 2001, p. A1.
"ES cells have plenty of limitations... For one, murine ES cells have a disturbing ability to form tumors, and researchers aren't yet sure how to counteract that. And so far reports of pure cell populations derived from either human or mouse ES cells are few and far between fewer than those from adult stem cells."
-Gretchen Vogel, "Can Adult Stem Cells Suffice?", Science, Vol. 292 (June 8, 2001), pp. 1820-1822 at 1822.
"Rarely have specific growth factors or culture conditions led to establishment of cultures containing a single cell type.... [T]he possibility arises that transplantation of differentiated human ES cell derivatives into human recipients may result in the formation of ES cell-derived tumors... Irrespective of the persistence of stem cells, the possibility for malignant transformation of the derivatives will also need to be addressed."
-J. S. Odorico et al, "Multilineage differentiation from human embryonic stem cell lines," Stem Cells Vol. 19 (2001), pp. 193-204 at 198 and 200, at http://stemcells.alphamedpress.org/cgi/reprint/19/3/193.pdf.
Read the original post:
Practical Problems with Embryonic Stem Cells - usccb.org
- Diabetes breakthrough: Revolutionary stem cell technique treated 'severe' disease in study - Daily Express - November 22nd, 2021
- The Role of Quality and Speed in Custom Model Generation - FierceBiotech - October 5th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Stem cells may be the key to saving white rhinos from extinction - Sciworthy - October 5th, 2021
- Global Allogenic Stem Cell Therapy Market 2021 Size, Share, Growth and Regional Analysis by Segmentation and Country Forecast to 2028 - Digital... - October 5th, 2021
- Human Embryonic Stem Cells Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 The Courier - The Courier - June 8th, 2021
- Conversion of mouse embryonic fibroblasts into neural crest cells and functional corneal endothelia by defined small molecules - Science Advances - June 8th, 2021
- Global Stem Cells Market Regulations and Competitive Landscape Outlook, 2020 to 2025 The Courier - The Courier - June 8th, 2021
- Global cell isolation market was valued at USD7013.71 million in 2020 and is anticipated to reach USD15529.45 million by 2026 - Yahoo Finance - June 8th, 2021
- Human blastocyst-like structures generated entirely from pluripotent stem cells. Shifting the paradigm of developmental biology? - ESHRE - April 4th, 2021
- Human Embryonic Stem Cells (HESC) Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- ESI BIO, Thermo Fisher,... - April 4th, 2021
- New Michigan law requires those receiving Johnson & Johnson vaccine be told it was developed using stem cells | TheHill - The Hill - April 4th, 2021
- Xenobots 2.0 are Here and Still Developed With Frog Stem Cells - Unite.AI - April 4th, 2021
- Global Human Embryonic Stem Cells Industry Market 2021 In-depth Industry Analysis, Growth By 2027:Lonza Group Ltd., Life Technologies Corporation,... - April 4th, 2021
- AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update - Business Wire - April 4th, 2021
- Research Associate in Stem Cells and Regenerative Medicine job with KINGS COLLEGE LONDON | 246711 - Times Higher Education (THE) - February 17th, 2021
- Stem Cells Market Size 2021 by Share Growing Rapidly with Recent Trends, Size, Development, Revenue, Demand and Forecast to 2024 NeighborWebSJ -... - February 17th, 2021
- Cell transplant therapy could be a treatment for leading cause of blindness - The Denver Channel - February 17th, 2021
- Cellular Reprogramming Tools Market likely to touch new heights by end of forec - Business-newsupdate.com - February 17th, 2021
- Human Embryonic Stem Cells Market Analysis By Growth ... - February 9th, 2021
- Pros and Cons of embryonic stem cells - Pros an Cons - February 9th, 2021
- Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others - PRNewswire - February 9th, 2021
- Reactivation of the pluripotency program precedes formation of the cranial neural crest - Science Magazine - February 4th, 2021
- Should We Double The Age When Science Can Experiment On Babies? - 550 KTSA - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Missouri State Representative Indicted Over Alleged Stem Cell Therapy Scam - IFLScience - February 4th, 2021
- Global Human Embryonic Stem Cells Market increasing demand with Industry Professionalist |know the Brand Players forecast 2027 Jumbo News - Jumbo... - February 4th, 2021
- Push on to Allow Expanded Human-Embryo Research - National Review - February 4th, 2021
- Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 Murphy's Hockey Law - Murphy's Hockey Law - February 4th, 2021
- Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network - The Bisouv... - February 4th, 2021
- Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell... - January 30th, 2021
- Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |... - January 30th, 2021
- Stem Cell Manufacturing includes Attractiveness and Raw Material Analysis and Competitor Position Grid Analysis to 2027 | Merck KGaA, Thermo Fisher... - January 30th, 2021
- RNA Molecules Are Masters of Their Own Destiny Regulating Their Own Production Through a Feedback Loop - SciTechDaily - January 30th, 2021
- The chromosomal protein SMCHD1 regulates DNA methylation and the 2c-like state of embryonic stem cells by antagonizing TET proteins - Science Advances - January 23rd, 2021
- North America to be the Torchbearer to Stem Cell Characterization And Analysis Tools Market NeighborWebSJ - NeighborWebSJ - January 23rd, 2021
- New Research Grant Seeks to Clarify the Role Genes Play in Modulating Inflammation - NYU Langone Health - January 23rd, 2021
- JARID2 and AEBP2 regulate PRC2 in the presence of H2AK119ub1 and other histone modifications - Science Magazine - January 23rd, 2021
- DiNAQOR Acquires EHT Technologies GmbH to Advance Engineered Heart Tissue R&D Capabilities - PRNewswire - January 19th, 2021
- TBC1D3 promotes neural progenitor proliferation by suppressing the histone methyltransferase G9a - Science Advances - January 19th, 2021
- 'He was very honored in his work' - Mercer Island Reporter - December 28th, 2020
- Israeli biotech firm's ALS treatment shows safety of use in trials - The Jerusalem Post - December 16th, 2020
- Ca Bishops To Work w/ Govt on Vaccination Campaigns - Catholic Herald Online - December 14th, 2020
- Human Embryonic Stem Cells (HESC) Market 2019 | Analyzing The Impact Followed By Restraints, Opportunities And Projected Developments | DataIntelo -... - December 6th, 2020
- Stem Cell Market Technology 2021 and Application, Segmentation by Leading Global Players, Market Status by Share and Size Forecast to 2024 - The... - December 6th, 2020
- Stem Cell Therapy Market Size, Opportunities, Dynamic, Outlook and Forecast To 2027 - Cheshire Media - December 6th, 2020
- Stem Cells Market will grow at CAGR of 8.61% by 2027 Cheshire Media - Cheshire Media - December 6th, 2020
- Stem Cell Medical Research to Expand in California Following Passage of Prop. 14 - Times of San Diego - November 27th, 2020
- Mechanisms of Telomere Protection Are Unique in Stem Cells - Technology Networks - November 27th, 2020
- Stem Cells Market by 2020 Research Report by Manufactures, Types, Applications, Regions and Trends to 2024 | Absolute Reports - The Market Feed - November 25th, 2020
- Autologous Stem Cell Based Therapies Market Share, Growth by Top Company, Region, Application, Driver, Trends & Forecasts by 2026 - PRnews Leader - November 25th, 2020
- Stem Cells Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors | (2020-2027),... - November 25th, 2020
- Stem Cells Market 2020: Rising with Immense Development Trends across the Globe by 2027 - The Market Feed - November 25th, 2020
- Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act - Yahoo Finance - November 25th, 2020
- Stem Cell Characterization and Analysis Tool Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19... - November 25th, 2020
- Autologous Stem Cell Based Therapies Market 2020 Emerging Trend and Advancement - News by aeresearch - November 9th, 2020
- Human Embryonic Stem Cells (HESC) Market 2020 Manufacturer Analysis, Emerging Trends, Top Companies and Forecast to 2027 - TechnoWeekly - November 7th, 2020
- Voters asked to approve $5.5 billion for stem cell research - Lebanon Express - November 7th, 2020
- Transcriptional priming as a conserved mechanism of lineage diversification in the developing mouse and human neocortex - Science Advances - November 7th, 2020
- Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - PRnews Leader - November 7th, 2020
- U.S. elections bring wins and losses for research community - Science Magazine - November 5th, 2020
- Stem Cell Therapy Market Size, Key Development Trends, and Growth Projection to 2027 - Stock Market Vista - November 5th, 2020
- Global Stem Cells Market 2020 Industry Outlook, Growth, Comprehensive Insights and Forecast 2025 - PRnews Leader - November 5th, 2020
- Panelists debate the implications and ethics of stem cell research - Johns Hopkins News-Letter - October 30th, 2020
- Stem Cell and Regenerative Therapy Market to Remain Balanced During the the COVID-19 Period - re:Jerusalem - October 30th, 2020
- Study Identifies Pitfall for Correcting Mutations in Human Embryos with CRISPR - Columbia University Irving Medical Center - October 30th, 2020
- Yale New Haven Health Docs: Interpreting the Uptick in Covid-19 Cases - Greenwich Free Press - October 30th, 2020
- Is the Pro-Life Movement on a Collision Course with the Coronavirus? - The Dispatch - October 29th, 2020
- Outlook for stem cell therapy - its role in tendon regeneration - different treatments for horse tendon injuries - Trainer Magazine - October 29th, 2020
- Yale Health advises against large Thanksgiving gatherings; eastern Connecticut now considered a 'hot spot' - The Westerly Sun - October 29th, 2020
- Stem Cell Therapy Market to Register Unwavering Growth During 2025 - The Think Curiouser - October 29th, 2020
- Human Embryonic Stem Cells (HESC) Market Share, Analysis and In-depth Research on Market Size, Trends, Emerging Growth Factors and Regional Forecasts... - October 20th, 2020
- COVID-19 Analysis to Understand the Competitive Outlook of Human Embryonic Stem Cells (HESC) Market - The Think Curiouser - October 20th, 2020
- Competitive Landscape of Human Embryonic Stem Cells (HESC) Market 2020 | Global Industry Size, Volume, Trends and Revenue Forecast to 2025 - The Think... - October 20th, 2020
- Stem Cells Market 2020 is predicted to rise with a CAGR of XX% by 2026 | Including Growth Prospect, Market Size & Growth, Key Vendors, Top most... - October 20th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 20th, 2020
- Global Stem Cell Manufacturing Market: Industry Analysis and forecast 2019 2027: By Product, Application, End-Users and Region - Stock Market Vista - October 20th, 2020
- The Infodemic: Was Regeneron COVID-19 Treatment Developed Using Stem Cells and Fetal Tissue? - Voice of America - October 15th, 2020
- COVID-19 Impact on Global Human Embryonic Stem Cells Market 2020 Industry Overview, Demand and Insights Analysis Report by 2026 ESI BIO, Thermo... - October 15th, 2020
- Yes on 14 | Mailbox | independentnews.com - Livermore Independent - October 15th, 2020